View in EDS

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.

Saved in:
Bibliographic Details
Title: Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.
Authors: Shah NN; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI., Zinzani PL; Istituto di Ematologia 'Seràgnoli,' IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy., Wang M; Department of Lymphoma & Myeloma, MD Anderson Cancer Center, Houston, TX., Nasta SD; Division of Hematology Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Lech-Maranda E; Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Ogawa Y; Department of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan., Fakhri B; Division of Hematology, Stanford University School of Medicine, Stanford, CA., Kuss B; Haematology and Molecular Genetics, Flinders Medical Centre and Flinders University, Bedford Park, SA, Australia., Miyashita K; Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan., Patel K; Sarah Cannon Research Institute, Nashville, TN., Coombs CC; Division of Hematology/Oncology, University of California Irvine, Irvine, CA., Ma S; Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL., Patel MR; Florida Cancer Specialists, Sarasota, FL.; Sarah Cannon Research Institute, Nashville, TN., Barve MA; Mary Crowley Cancer Research, Dallas, TX., Tessoulin B; Nantes University School of Medicine and University Hospital, Nantes, France., Stathis A; New Drugs Development Unit, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland., Ennishi D; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan., Hashimoto D; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan., Kojima K; Department of Hematology, Kochi Medical School Hospital, Nankoku, Japan., Zelenetz AD; Memorial Sloan Kettering Cancer Center, New York, NY., Cohen JB; Winship Cancer Institute, Emory University, Atlanta, GA., Vose JM; Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE., Maddocks KJ; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Munir T; Department of Haematology, St James's University Hospital, Leeds, United Kingdom., Sun F; Eli Lilly and Company, Indianapolis, IN., Bian Y; Eli Lilly and Company, Indianapolis, IN., Balbas M; Eli Lilly and Company, Indianapolis, IN., Tsai DE; Eli Lilly and Company, Indianapolis, IN., Abada P; Eli Lilly and Company, Indianapolis, IN., Cheah CY; Linear Clinical Research, Sir Charles Gairdner Hospital and University of Western Australia, Nedlands, WA, Australia.
Source: Blood advances [Blood Adv] 2025 Dec 09; Vol. 9 (23), pp. 5954-5964.
Publication Type: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I; Multicenter Study
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40845254
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Shah+NN%22">Shah NN</searchLink>; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI.<br /><searchLink fieldCode="AU" term="%22Zinzani+PL%22">Zinzani PL</searchLink>; Istituto di Ematologia 'Seràgnoli,' IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.; Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.<br /><searchLink fieldCode="AU" term="%22Wang+M%22">Wang M</searchLink>; Department of Lymphoma & Myeloma, MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Nasta+SD%22">Nasta SD</searchLink>; Division of Hematology Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Lech-Maranda+E%22">Lech-Maranda E</searchLink>; Institute of Hematology and Transfusion Medicine, Warsaw, Poland.<br /><searchLink fieldCode="AU" term="%22Ogawa+Y%22">Ogawa Y</searchLink>; Department of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.<br /><searchLink fieldCode="AU" term="%22Fakhri+B%22">Fakhri B</searchLink>; Division of Hematology, Stanford University School of Medicine, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Kuss+B%22">Kuss B</searchLink>; Haematology and Molecular Genetics, Flinders Medical Centre and Flinders University, Bedford Park, SA, Australia.<br /><searchLink fieldCode="AU" term="%22Miyashita+K%22">Miyashita K</searchLink>; Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.<br /><searchLink fieldCode="AU" term="%22Patel+K%22">Patel K</searchLink>; Sarah Cannon Research Institute, Nashville, TN.<br /><searchLink fieldCode="AU" term="%22Coombs+CC%22">Coombs CC</searchLink>; Division of Hematology/Oncology, University of California Irvine, Irvine, CA.<br /><searchLink fieldCode="AU" term="%22Ma+S%22">Ma S</searchLink>; Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Patel+MR%22">Patel MR</searchLink>; Florida Cancer Specialists, Sarasota, FL.; Sarah Cannon Research Institute, Nashville, TN.<br /><searchLink fieldCode="AU" term="%22Barve+MA%22">Barve MA</searchLink>; Mary Crowley Cancer Research, Dallas, TX.<br /><searchLink fieldCode="AU" term="%22Tessoulin+B%22">Tessoulin B</searchLink>; Nantes University School of Medicine and University Hospital, Nantes, France.<br /><searchLink fieldCode="AU" term="%22Stathis+A%22">Stathis A</searchLink>; New Drugs Development Unit, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.<br /><searchLink fieldCode="AU" term="%22Ennishi+D%22">Ennishi D</searchLink>; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.<br /><searchLink fieldCode="AU" term="%22Hashimoto+D%22">Hashimoto D</searchLink>; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan.<br /><searchLink fieldCode="AU" term="%22Kojima+K%22">Kojima K</searchLink>; Department of Hematology, Kochi Medical School Hospital, Nankoku, Japan.<br /><searchLink fieldCode="AU" term="%22Zelenetz+AD%22">Zelenetz AD</searchLink>; Memorial Sloan Kettering Cancer Center, New York, NY.<br /><searchLink fieldCode="AU" term="%22Cohen+JB%22">Cohen JB</searchLink>; Winship Cancer Institute, Emory University, Atlanta, GA.<br /><searchLink fieldCode="AU" term="%22Vose+JM%22">Vose JM</searchLink>; Division of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE.<br /><searchLink fieldCode="AU" term="%22Maddocks+KJ%22">Maddocks KJ</searchLink>; Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.<br /><searchLink fieldCode="AU" term="%22Munir+T%22">Munir T</searchLink>; Department of Haematology, St James's University Hospital, Leeds, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Sun+F%22">Sun F</searchLink>; Eli Lilly and Company, Indianapolis, IN.<br /><searchLink fieldCode="AU" term="%22Bian+Y%22">Bian Y</searchLink>; Eli Lilly and Company, Indianapolis, IN.<br /><searchLink fieldCode="AU" term="%22Balbas+M%22">Balbas M</searchLink>; Eli Lilly and Company, Indianapolis, IN.<br /><searchLink fieldCode="AU" term="%22Tsai+DE%22">Tsai DE</searchLink>; Eli Lilly and Company, Indianapolis, IN.<br /><searchLink fieldCode="AU" term="%22Abada+P%22">Abada P</searchLink>; Eli Lilly and Company, Indianapolis, IN.<br /><searchLink fieldCode="AU" term="%22Cheah+CY%22">Cheah CY</searchLink>; Linear Clinical Research, Sir Charles Gairdner Hospital and University of Western Australia, Nedlands, WA, Australia.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101698425%22">Blood advances</searchLink> [Blood Adv] 2025 Dec 09; Vol. 9 (23), pp. 5954-5964.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Clinical Trial, Phase I; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Hematology%22">American Society of Hematology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101698425 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2473-9537 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2224739529%22">24739529 </searchLink><i>NLM ISO Abbreviation: </i>Blood Adv <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40845254
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/bloodadvances.2024014975
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 5954
    Titles:
      – TitleFull: Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Shah NN
      – PersonEntity:
          Name:
            NameFull: Zinzani PL
      – PersonEntity:
          Name:
            NameFull: Wang M
      – PersonEntity:
          Name:
            NameFull: Nasta SD
      – PersonEntity:
          Name:
            NameFull: Lech-Maranda E
      – PersonEntity:
          Name:
            NameFull: Ogawa Y
      – PersonEntity:
          Name:
            NameFull: Fakhri B
      – PersonEntity:
          Name:
            NameFull: Kuss B
      – PersonEntity:
          Name:
            NameFull: Miyashita K
      – PersonEntity:
          Name:
            NameFull: Patel K
      – PersonEntity:
          Name:
            NameFull: Coombs CC
      – PersonEntity:
          Name:
            NameFull: Ma S
      – PersonEntity:
          Name:
            NameFull: Patel MR
      – PersonEntity:
          Name:
            NameFull: Barve MA
      – PersonEntity:
          Name:
            NameFull: Tessoulin B
      – PersonEntity:
          Name:
            NameFull: Stathis A
      – PersonEntity:
          Name:
            NameFull: Ennishi D
      – PersonEntity:
          Name:
            NameFull: Hashimoto D
      – PersonEntity:
          Name:
            NameFull: Kojima K
      – PersonEntity:
          Name:
            NameFull: Zelenetz AD
      – PersonEntity:
          Name:
            NameFull: Cohen JB
      – PersonEntity:
          Name:
            NameFull: Vose JM
      – PersonEntity:
          Name:
            NameFull: Maddocks KJ
      – PersonEntity:
          Name:
            NameFull: Munir T
      – PersonEntity:
          Name:
            NameFull: Sun F
      – PersonEntity:
          Name:
            NameFull: Bian Y
      – PersonEntity:
          Name:
            NameFull: Balbas M
      – PersonEntity:
          Name:
            NameFull: Tsai DE
      – PersonEntity:
          Name:
            NameFull: Abada P
      – PersonEntity:
          Name:
            NameFull: Cheah CY
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 12
              Text: 2025 Dec 09
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2473-9537
          Numbering:
            – Type: volume
              Value: 9
            – Type: issue
              Value: 23
          Titles:
            – TitleFull: Blood advances
              Type: main
ResultId 1